Axon Therapies Inc.

Axon Therapies Inc. is a private medical technology company based in Santa Clara, California, focused on innovative treatments for heart failure. The company has developed a minimally invasive, implant-free therapy known as Splanchnic Ablation for Volume Management (SAVM), utilizing its proprietary Satera™ Ablation System. This catheter-based procedure targets the overactive sympathetic nervous system, which contributes to heart failure, with the goal of restoring volume balance and improving patient symptoms. The company is committed to advancing heart failure treatment by addressing the root causes of the disease. Axon Therapies is actively involved in clinical trials, including the REBALANCE-HF trial, which has shown promising early results. These findings have been shared at major cardiology conferences and published in peer-reviewed journals, highlighting the potential of their therapy in managing heart failure. Axon Therapies primarily collaborates with healthcare providers and clinical partners in cardiovascular care, aiming to offer advanced treatment options for patients experiencing volume overload due to sympathetic nervous system imbalance.

• Employees 9
• Founded 2016
• Annual Revenue $5700000
• Total Funding $35299999